| Followers | 2543 |
| Posts | 250732 |
| Boards Moderated | 34 |
| Alias Born | 05/06/2014 |
Tuesday, March 28, 2017 1:42:10 AM
$PMCB Analysts Review on Trending Stock: Pharmacyte Biotech Inc (PMCB)
http://theindependentrepublic.com/2017/03/27/analysts-review-on-trending-stock-pharmacyte-biotech-inc-pmcb-growlife-inc-phot-earth-science-tech-inc-etst/
Pharmacyte Biotech Inc (OTCMKTS:PMCB) showing dropped of -2.43% and closed at $0.0965, after gaining total volume of 1.39 million shares. Its earnings per share (EPS) is -$0.01 and its beta value stands at 2.44 points and has total market capitalization of $85.24 million and a total of 875.31 million outstanding shares.
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer based upon the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.
http://theindependentrepublic.com/2017/03/27/analysts-review-on-trending-stock-pharmacyte-biotech-inc-pmcb-growlife-inc-phot-earth-science-tech-inc-etst/
Pharmacyte Biotech Inc (OTCMKTS:PMCB) showing dropped of -2.43% and closed at $0.0965, after gaining total volume of 1.39 million shares. Its earnings per share (EPS) is -$0.01 and its beta value stands at 2.44 points and has total market capitalization of $85.24 million and a total of 875.31 million outstanding shares.
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer based upon the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.
investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
